Release Date: March 31, 2025

Expiration Date: March 31, 2026

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in glaucoma. In this educational program, these experts explore new and emerging MIGS procedures, surgical devices, diagnostic tools, imaging modalities, comanagement, and individualization of therapy—all of which have the potential to substantially improve outcomes in glaucoma patients.

This educational activity is an archive of the live symposium held on February 14, 2025.

Target Audience

This live educational activity is directed toward optometrists, ophthalmologists, and other eye care professionals.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Discuss the benefits of diagnostic tools and imaging modalities in glaucoma management
Describe the various surgical techniques for glaucoma management based on their mechanisms, safety profiles, and clinical outcomes
Apply patient selection criteria to determine the appropriate minimally invasive glaucoma surgery (MIGS) approach for individuals with varying glaucoma severity
Implement optimal strategies for comanagement of glaucoma between optometrists and ophthalmologists

Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

GET STARTED WITH THIS PROGRAM:

Create Account Already Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is accredited by COPE to provide continuing education to optometrists.

Physicians’ Education Resource^®, LLC, designates this activity for a maximum of 1.25 COPE credit.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Alcon, Glaukos Corporation, and Sun Pharmaceutical Industries, Inc.

Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

GET STARTED WITH THIS PROGRAM:

Related Content

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas